Achieve Life Sciences Stock (NASDAQ:ACHV)
Previous Close
$4.33
52W Range
$3.03 - $5.98
50D Avg
$4.72
200D Avg
$4.66
Market Cap
$147.53M
Avg Vol (3M)
$107.93K
Beta
1.58
Div Yield
-
ACHV Company Profile
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
ACHV Performance
Peer Comparison
| Ticker | Company |
|---|---|
| GRCL | Gracell Biotechnologies Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| CNSP | CNS Pharmaceuticals, Inc. |
| VECT | VectivBio Holding AG |
| NXTC | NextCure, Inc. |
| TCRX | TScan Therapeutics, Inc. |
| APLS | Apellis Pharmaceuticals, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| SPRO | Spero Therapeutics, Inc. |
| AVRO | AVROBIO, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| IMMX | Immix Biopharma, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| ITOS | iTeos Therapeutics, Inc. |
| HEPA | Hepion Pharmaceuticals, Inc. |
| NLTX | Neurogene Inc. |
| CHRS | Coherus BioSciences, Inc. |